Waters’ Transformative Merger with BD’s Biosciences: A Strategic Move for Long-term Growth

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Buy rating on Waters, with a price target of $500.00.

Puneet Souda has given his Buy rating due to a combination of factors surrounding Waters’ recent strategic moves. The company announced a significant merger with BD’s Biosciences and Dx Solutions, which is expected to be transformative. Despite initial investor concerns about the valuation and potential margin dilution, the long-term growth prospects appear promising.
The management’s projections suggest that the integration could lead to substantial revenue and EBITDA growth by 2030. Additionally, the anticipated synergies and the leadership’s track record in execution provide confidence in achieving these targets. While there are challenges, such as margin dilution, the potential for accretive EPS growth and the strategic benefits of the merger underpin the Buy rating.

Souda covers the Healthcare sector, focusing on stocks such as Quanterix, Exact Sciences, and Illumina. According to TipRanks, Souda has an average return of -9.8% and a 33.27% success rate on recommended stocks.

In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $336.00 price target.